
Keywords: سون آپ; AMD; age-related macular degeneration; ANCHOR; Anti-VEGF Antibody Fragment Ranibizumab for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD; CI; confidence interval; GA; geographic atrophy; HORIZON; An Open-Label, Multicenter Ext